David Gandara, MD, from the University of California, Davis, CA discusses the results of the OAK trial (NCT02008227) and how they impact the treatment landscape of advanced stage, non-small cell lung cancer (NSCLC). This is the first phase III trial to investigate the safety and efficacy of the anti-PD-L1 agent, atezolizumab, compared to docetaxel, in patients with NSCLC. The results indicated that there were better patient outcomes when the received atezolizumab, and this was also associated with high expression of PD-L1. Interestingly, even patients with no expression of PD-L1, showed some clinical benefit. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.